FDA “Not Approvable” Letter Questions Benefit Of Endo’s Frova In Menstrual Migraine
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency indicates potential for vascular events is another reason frovatriptan is "not approvable" for short-term prevention of menstrual migraine.